Creation of targeted genomic deletions using TALEN or CRISPR/Cas nuclease pairs in one-cell mouse embryos  by Brandl, Christina et al.
FEBS Open Bio 5 (2015) 26–35journal homepage: www.elsevier .com/locate / febsopenbioMethodCreation of targeted genomic deletions using TALEN or CRISPR/Cas
nuclease pairs in one-cell mouse embryoshttp://dx.doi.org/10.1016/j.fob.2014.11.009
2211-5463/ 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Abbreviations: DSB, double-strand break; ES, embryonic stem (cell); HR,
homologous recombination; NHEJ, non-homologous end joining; sg, single guide;
TAL, transcription activator-like; TALEN, TAL effector nucleases; ZFN, zinc-ﬁnger
nucleases
⇑ Corresponding authors at: Institute of Developmental Genetics, Helmholtz
Zentrum München, German Research Center for Environmental Health, 85764
Neuherberg, Germany (W. Wurst). Max-Delbrück-Centrum für Molekulare Medizin,
Robert-Roessle-Str. 10, 13125 Berlin, Germany. Tel.: +49 30 9406 2832; fax: +49 89
9406 2850 (R. Kühn).
E-mail addresses: Christina.brandl@helmholtz-muenchen.de (C. Brandl), oskar.
ortiz@helmholtz-muenchen.de (O. Ortiz), bernhard86@web.de (B. Röttig), benedikt.
wefers@helmholtz-muenchen.de (B. Wefers), wurst@helmholtz-muenchen.de
(W. Wurst), ralf.kuehn@mdc-berlin.de (R. Kühn).Christina Brandl a,b, Oskar Ortiz a, Bernhard Röttig a,b, Benedikt Wefers a,c, Wolfgang Wurst a,b,c,d,e,⇑,
Ralf Kühn a,b,f,⇑
a Institute of Developmental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, 85764 Neuherberg, Germany
b Technische Universität München, 85350 Freising-Weihenstephan, Germany
cDeutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE), 80336 Munich, Germany
dMax-Planck-Institute of Psychiatry, 80804 Munich, Germany
eMunich Cluster for Systems Neurology (SyNergy), Ludwig-Maximilians-Universität München, 80336 Munich, Germany
fMax-Delbrück-Centrum für Molekulare Medizin (MDC), 13125 Berlin, Germany
a r t i c l e i n f oArticle history:
Received 4 October 2014
Revised 25 November 2014
Accepted 27 November 2014
Keywords:
TALENs
Disease model
One-cell embryo
Mouse mutant
CRISPR
Cas9a b s t r a c t
The use of TALEN and CRISPR/CAS nucleases is becoming increasingly popular as a means to edit sin-
gle target sites in one-cell mouse embryos. Nevertheless, an area that has received less attention
concerns the engineering of structural genome variants and the necessary religation of two distant
double-strand breaks. Herein, we applied pairs of TALEN or sgRNAs and Cas9 to create deletions in
the Rab38 gene. We found that the deletion of 3.2 or 9.3 kb, but not of 30 kb, occurs at a frequency of
6–37%. This is sufﬁcient for the direct production of mutants by embryo microinjection. Therefore,
deletions up to 10 kb can be readily achieved for modeling human disease alleles. This work rep-
resents an important step towards the establishment of new protocols that support the ligation of
remote DSB ends to achieve even larger rearrangements.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Since 1988, gene targeting in embryonic stem (ES) cells has
enabled the generation of mouse mutants and the study of gene
function by reverse genetics [1]. It has also transpired that
sequence-speciﬁc nucleases can be used as an alternative to induce
targeted double-strand breaks (DSB) and enhance local DNA repair.
Thus, it is possible to produce mutants from one cell embryos,
independent of ES cells [2]. The proof-of-principle for this muta-genesis approach was provided by the Zinc-ﬁnger nucleases
(ZFN). Nevertheless, this system was not convenient since ZFNs
cannot be easily programmed for the recognition of new target
sequences. This problem was circumvented with the determina-
tion that transcription activator-like (TAL) proteins of Xanthomonas
follow a simple modular code for DNA recognition [3] and were
suitable for gene editing by fusion with the FokI nuclease domain
into TAL effector nucleases (TALEN) [4]. The latest, third generation
of nucleases is provided by the CRISPR/Cas9 bacterial defense sys-
tem. This approach uses short, single guide (sg) RNAs for DNA
sequence recognition and can be programmed towards new targets
by adaption of the sgRNA ﬁrst 20 nucleotides that determine the
speciﬁcity of the system [5]. The sgRNAs are bound by the generic,
two domain nuclease Cas9 and will guide the binary complex to
the complementary DNA sequence for DSB induction. These DSBs
are then either repaired by homologous recombination (HR)
together with gene targeting vectors [6,7] or become, in the
absence of repair templates, religated by non-homologous end
joining (NHEJ). This is frequently accompanied by the loss of multi-
ple nucleotides [8]. HR-mediated repair of nuclease-induced DSBs
enables the insertion of preplanned sequence alterations into the
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used for the generation of frameshift mutations.
Both, TALEN and CRISPR/Cas nucleases were successfully
applied for creating germline mutations in a variety of species
[5]. In mice nuclease expression in one-cell embryos has been used
for the generation of knockout alleles, codon replacements and the
insertion of reporter genes or loxP sites [9–12]. Besides mutations
addressing single target genes, structural genome rearrangements
such as large deletions and duplications, as well as inversions and
translocations, represent an important subset of mutations associ-
ated with epilepsy, autism, schizophrenia and cancer [13,14]. For
engineering of such alleles in ES cells sequential steps of gene tar-
geting are required. The generation of structural variants via nucle-
ase technology requires the simultaneous processing of two distant
sites in a single cell. This is an area that is yet poorly explored by
the use of TALEN or CRISPR/Cas in mouse embryos.
Here we applied two pairs of TALEN or two sgRNAs to generate
genomic deletions in one cell mouse embryos. Since the simulta-
neous processing of two unrelated DSBs and the sealing of their
distant ends are required for deletion, it was an open question
whether such events occur at a reasonable frequency. This is given
that a limited number of embryos can be handled in microinjection
experiments. Furthermore, we explored whether NHEJ or HR pro-
vides the most efﬁcient pathway for the sealing of distant DSB
ends. As a model system, we used two TALEN pairs or sgRNAs spe-
ciﬁc to the Rab38 gene that we previously targeted at a single site
using ZFNs or TALEN [11,12]. We found that the deletion of 3.2 or
9.3 kb, but not of 30 kb occurs by NHEJ repair at a frequency (6–
37%), sufﬁcient for the direct production of mutants by embryo
microinjection. Thus, genomic deletions in the scale of up to
10 kb can be readily achieved using established nuclease technol-
ogy. Nevertheless, the construction of larger rearrangements
requires the development of new techniques and protocols sup-
porting the end joining between distant DSBs.
2. Results
2.1. Generation of mice harboring a 9.3 kb deletion in Rab38 using
TALENs
To explore whether genomic deletions can be generated using
two pairs of TALEN, each deﬁning one endpoint of the intended
deletion, we used a previously described TALEN against the ﬁrst
exon of Rab38 [11] (TAL-A1/2, Fig. 1A). We then constructed a sec-
ond TALEN recognizing a sequence within the ﬁrst intron, at a dis-
tance of 9.3 kb (TAL-B1/2, Fig. 1A). TAL-B1/2 was designed using
our TALENdesigner software and cloned by a modular construction
protocol into an expression vector, as described [11]. Upon
cotransfection of HEK 293 cells with the A1/2 or B1/2 pair of TALEN
expression and nuclease reporter plasmids [11] harboring the
selected target sequences both TALEN pairs were found to exhibit
speciﬁc nuclease activity (Supplementary Fig. 1A). The presence of
two neighboring DSBs may be sufﬁcient for removal of the inter-
vening genomic segment at a reasonable frequency. Alternatively,
each DSB could be independently closed by NHEJ repair such that
the distant ends of both DSBs may be rarely connected. To further
support targeted deletions, we sought to provide a template for HR
repair and designed the single-stranded oligodeoxynucleotide
ODN(A/B) covering 62 bp of sequence upstream of the TAL-A1 site
and 61 bp downstream of the TAL-B2 site, bridging the ends of the
intended deletion in between an additional BamHI restriction site
(Fig. 1A). For deletion of the 9.3 kb Rab38 gene segment ﬂanked
by the A1/2 and B1/2 recognition sites, four TALEN mRNAs and
ODN (A/B) were microinjected into the pronuclei of mouse one-cell
embryos. Upon embryo transfer we obtained 33 pups that were
genotyped by PCR analysis of tail DNA using the primer pairP-for/P-del for the detection of deleted alleles (Fig. 1A). PCR prod-
ucts of 324 bp are predicted in case the deletion endpoints reach
exactly the center of the TALEN spacer sequences. Two of these
mice (6%) were identiﬁed as mutant founders (AB3, AB25) by the
presence of the predicted PCR bands (Fig. 1B). Subcloning and
sequence analysis of these PCR products proved the deletion of
9355 bp in both founders, covering sequences located 3 bp down-
stream of the TALEN site A1 and 6 bp upstream of the site B2
(Rab38D9.3 allele, Fig 1C). Both alleles were not recombined with
ODN (A/B), as indicated by the absence of the new BamHI site,
but are likely generated by NHEJ between the DSBs at the A1/2
and B1/2 target sites. To further characterize the frequency of small
deletions occurring at the TALEN target sites we ampliﬁed the
regions spanning the target site A1/2 or B1/2 from all 33 pups.
The sequence analysis of these PCR products showed that hetero-
zygous, small deletions (4–11 bp) occurred in three pups (#18,
#21, #22) at the target site A1/2 and in one pup (#21; 1 bp dele-
tion) at the B1/2 target site, altogether conﬁrming the activity of
TALENs in 6 of 33 (18%) of pups. In addition, PCR products spanning
the A1/2 target site from the founders AB3 and AB25 showed
reduced size (Fig. 1D), suggesting the presence of small deletions
in their second Rab38 allele. Subcloning and sequence analysis of
these PCR products revealed the loss of 11 bp in founder AB3 and
of 25 bp in founder AB25, respectively, within the TALEN target site
A1/2 (Fig. 1E). Since the target site A1/2 is located within the ﬁrst
exon of Rab38, both alleles of founders AB3 and AB25 were pre-
dicted to be inactivated either by the 9.3 kb targeted deletion or
the translational frameshift within exon 1. Since the G19V replace-
ment of RAB38 leads to impaired pigment production and choco-
late fur color on the black C57BL/6 background [15], we reasoned
that the knockout of Rab38 may also lead to a lighter coat on the
agouti background we used for embryo microinjection. Upon mac-
roscopic inspection the coat of founders AB25 and AB3 exhibited a
lighter agouti color as compared to Rab38wt littermates (Fig. 1F).
The reduced pigmentation of the Rab38 mutants was further con-
ﬁrmed by the microscopic comparison of dorsal awl hairs
(Fig. 1F). To demonstrate the germline transmission of the
Rab38D9.3 allele and for the establishment of breeding colonies,
both male founders were bred to wildtype females. The progeny
was analyzed for the presence of the Rab38D9.3 allele using the
PCR primer pair P-for/P-del. As indicated by the presence of the
316 bp band, the Rab38D9.3 allele was identiﬁed in 6 of 12 pups
and in 3 of 9 pups derived from founder AB3 or AB25, respectively
(Fig. 2A). Subcloning and sequencing of the PCR products from the
pups AB3#1 and AB25#2 conﬁrmed the identity of the transmitted
and the parental Rab38D9.3 alleles (Fig. 2B). These results show that
two pairs of TALEN can be used for the single step deletion of a
9.3 kb gene segment by NHEJ in one-cell embryos and that the
mutant alleles are germline transmitted. In addition, we found that
the presence of an ODN bridging the deletion endpoints does not
further support recombination and that homozygous compound
mutants exhibiting a mutant phenotype can be obtained in the
F0 generation.
2.2. Generation of genomic deletions using the CRISPR/Cas system
As an alternative to the use of TALEN, we explored generating
genomic deletions by CRISPR/Cas mediated mutagenesis using
pairs of sgRNAs. Within the Rab38 gene we used the upstream tar-
get site Rab38-2 located within the ﬁrst exon of Rab38 together
with each one of four distant sgRNA sites at a distance of 3.2 kb,
10.4 kb, 31.8 kb or 51.8 kb (Fig. 3A). To conﬁrm the activity of
our CRISPR/Cas vectors, nuclease reporter plasmids were con-
structed and cotransfected into mouse neuroblastoma (Neuro2A)
cells. This analysis showed that both TALEN pairs and sgRNAs exhi-
bit high nuclease activity against the respective target sequences
Fig. 1. Deletion of a 9.3 kb Rab38 gene segment in one-cell embryos using two pairs of TALEN. (A) Schematic diagram of the Rab38 gene and the planned deletion of 9.3 kb
(Rab38D9.3 allele), indicating the position of the ﬁrst exon, of the TALEN recognition sites and PCR primer pairs. (B) PCR detection of Rab38D9.3 alleles using primers P-forA and
P-del using tail DNA from 31 pups derived from embryos microinjected with TAL-A1/2 and TAL-B1/2 mRNAs. M: size marker, +: positive control, : negative control. (C)
Sequence comparison of cloned PCR products from founders AB3 and AB25 with the Rab38 wildtype locus, indicating identical deletions of 9355 bp in both founders. The
deletion endpoints are located within the TALEN spacer regions. The upstream deletion endpoint disrupts codon 31, followed by a random translational frame. (D) PCR
analysis of the TAL-A1/2 target region with tail DNA from 31 pups derived frommicroinjected embryos using primers P-forA and P-revA. The PCR products ampliﬁed from the
second Rab38 allele of founders AB3 and AB25 show reduced size, indicating the presence of small deletions. (E) Sequence analysis of cloned PCR products (see D) showing the
deletion of 11 bp or of 25 bp within the TAL-A1/2 target region of the second Rab38 allele of founder AB3 or AB25, respectively. The translation of the TAL-A1/2 target
sequence within the ﬁrst exon of Rab38 shows reading frameshifts after codon 31 (AB3) or 27 (AB25). (F) Comparison of the coat color of founder AB25 with an agouti colored
littermate control (Rab38wt) and of dorsal awls showing the reduced pigmentation of hairs in the mutant (20 magniﬁcation).
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Fig. 2. Germline transmission of Rab38D9.3 alleles. (A) PCR detection of Rab38D9.3 alleles using primers P-forA and P-del with tail DNA from pups derived from founder AB3 or
AB25. M: size marker, +: positive control, : negative control. (B) Sequence comparison of cloned PCR products (see A) derived from pups AB3-1 and AB25-2 with the parental
Rab38D9.3 allele.
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paired CRISPR/Cas system by cotransfecting Cas9 and pairs of
sgRNA expression vectors into Neuro2A cells, followed by PCR
analysis for the detection of genomic deletions. To induce genomic
deletions four pairs of sgRNA vectors were cotransfected with a
Cas9 expression vector into Neuro2A cells and two days later geno-
mic DNA was isolated from the transfected samples. These were
then qualitatively analyzed for deletion events using primer pairs
positioned at both sides of the intended breakpoints for the ampli-
ﬁcation of 300–400 bp fragments. For all tested combinations of
Cas9 and the sgRab38-2/-3, -2/-10, -2/-32 and -2/-52 vectors we
detected PCR products indicating the presence of genomic dele-
tions of 3.2 kb, 10.4 kb, 31.8 kb or 51.7 kb, respectively; these were
absent in the nontransfected negative control (Fig. 3B). These PCR
products were cloned and the sequence analysis conﬁrmed that all
intended deletions occurred in between the known cleavage site of
Cas9, 3 bp upstream of each PAM sequence, without the removal or
insertion of additional nucleotides (Fig. 3C). To introduce such
deletions into the mouse genome, we microinjected Cas9 mRNA
and the sgRNA pairs sgRab38-2/-3 or sgRab38-2/-32 into one-cell
embryos. In addition, to enable DSB repair by HR, we included a
single-stranded oligodeoxynucleotide (ODND2/3) covering 65 bp
upstream of the sgRab38-2 site and 61 bp downstream of the
sgRab38-3 site, bridging the deletion endpoints. From the microin-
jection of Cas9 and sgRab38-2/-32 we obtained 38 pups that were
genotyped by PCR analysis of tail DNA for the presence of the
intended deletion using the primer pair P-for/P-del32. None of
the pups showed the predicted 383 bp PCR band, indicating that
the frequency of a >30 kb genomic deletion falls below the level
of 3%. From the microinjection of Cas9 and sgRab38-2/-3 we
obtained 27 pups that were genotyped by PCR analysis of tail
DNA for the presence of the intended 3.2 kb deletion using the pri-
mer pair P-for/P-del3. In this case ten of the 27 pups (37%) wereidentiﬁed as mutant founders by the presence of the expected
326 bp PCR band in eight samples or by larger PCR fragments
in founder #9 and 23, representing noncanonical recombination
events (Fig. 4A). The cloning and sequence analysis of up to ﬁve
PCR products per founder showed the presence of a single deleted
Rab38 allele (Rab38D3.2) in four founders and of two divergent
mutant alleles in six founders (Fig. 4B). Only one of these alleles
(founder #23) resulted from HR with ODND2/3 as indicated by
the presence of an indicative, additional BamHI site. Among the
15 alleles repaired by NHEJ, four junctions were precisely joined
at the Cas9 cleavage sites, whereas 11 alleles lost 1–19 bp, with a
2 bp insertion in one case. Founder #9 and #23 showed one allele
resulting from the predicted repair of Cas9 induced DSBs by NHEJ
or HR, despite the fact that only larger products were visibly ampli-
ﬁed (Fig. 4A). The other mutant alleles of these founders showed
the intended processing at the sgRab38-2/3 target sites but the
unexpected insertion of sequences identical to genomic regions
located upstream (397 bp insertion, #9b) or downstream (163 bp
insertion, #23b) of the sgRab38-3 target site.
In addition, we ampliﬁed from all 27 pups genomic segments
spanning the sgRab38-2 (Fig. 4A) or sgRab38-3 regions (data not
shown) to assess the frequency of small deletions occurring at sin-
gle target sites. The sequence analysis of these PCR products
revealed that small deletions (3–138 bp) or insertions (1 bp)
occurred at both, the sgRab38-2 and sgRab38-3 target regions on
the second Rab38 locus in 5 of 7 of founders (#7, #9, #12, #26,
#27) harboring a Rab38D3.2 allele. In the founders #18 and #19
as well as the 17 pups without a Rab38D3.2 allele, both sgRab38 tar-
get regions were found intact. As found in the TALEN induced
Rab38D9.3 mutants, these results point to a high nuclease activity
in founders harboring a Rab38D3.2 allele, frequently leading to the
co-processing of the second Rab38 locus. From the tail DNA of
founders #6, #8, and #23 we could not obtain the predicted PCR
Fig. 3. Deletion of Rab38 gene segments in Neuro2A cells using the CRISPR/Cas system. (A) Schematic diagram of the Rab38 gene and the planned deletions of 3.2–51.7 kb,
indicating the position of the ﬁrst exon, of sgRNA target sites and of PCR primers. (B) Detection of deleted Rab38 alleles 2 days after transfection of Neuro2A cells with
expression vectors for Cas9 and sgRab38-2 together with sgRab38-3 (D2-3), sgRab38-10 (D2-10), sgRab38-32 (D2-32), or sgRab38-52 (D2-52). M: size marker, : negative
control. (C) Sequence comparison of the Rab38 gene with PCR products derived from transfected Neuro2A cells (see B), conﬁrming the authenticity of deleted alleles. In all
cases the deletion endpoints were located at the predicted DSB sites 3 bp upstream of the target’s PAM sequences (arrowheads).
30 C. Brandl et al. / FEBS Open Bio 5 (2015) 26–35bands from both sgRNA target regions, suggesting that in these
founders both Rab38 loci were processed by Cas9, resulting into a
homozygous Rab38D3.2 genotype. From the cloning of ﬁve products
of the Rab38D3.2 PCR reaction from each of these founders we iden-
tiﬁed two mutant alleles in founder #6 and #23 but only one
deleted allele in founder #8. By this analysis we either missed a
potential secondmutant allele of founder #8 or both mutant alleles
show identical sequences. In the absence of Rab38 wildtype alleles
in the melanocyte population, the homozygous mutants #6, #8
and #23 can be expected to exhibit a coat color phenotype, as seen
in the TALEN induced Rab38mutants. Indeed these founders exhib-
ited a lighter coat as compared to agouti colored, Rab38wt controls
(Fig. 4C). The microscopic inspection of dorsal awls from founder
#8 conﬁrmed the reduced pigmentation of the mutant (Fig. 4C).
To assess the processing of off-target sites in microinjected
embryos, we ampliﬁed and sequenced three genomic regions each
related to the sgRab38-2 or sgRab38-3 target sequence using tail
DNA of all founder mutants. Besides the identiﬁcation of a known
single nucleotide polymorphism in one of the regions of founder
#9, we did not ﬁnd evidence for the processing of these sites by
CRISPR/Cas (Supplementary Fig. 2). To demonstrate the germline
transmission of the Rab38D3.2 alleles and for the establishment of
breeding colonies, ﬁve mutant founders were bred to wildtype
females. Tail DNA of the resulting progeny was analyzed for the
presence of mutant Rab38 alleles using the PCR primer pair P-for/
P-del. Only about half of the pups derived from the putativebiallelic-mutated founders #6 (7/15 pups) and #8 (4/8 pups) were
PCR positive (Fig. 5A), indicating a mosaic distribution of mutant
alleles in the germline of these founders. The sequence analysis
of ﬁve (#6) or three (#8) PCR products conﬁrmed their identity
with the founder’s allele #6a and #6b or #8, respectively
(Fig. 5B). From founder #23 all of the eight pups analyzed harbored
either the allele #23a recombined with ODND2/3 (5 pups) or allele
#23b (3 pups), conﬁrming the homozygous mutant state in this
founders’s germline (Fig. 5A and B). Founder #9 transmitted only
the aberrantly recombined allele #9b to 4 of 6 pups whereas foun-
der #26 transmitted allele #26a to one pup and allele #26b to six
of nine pups (Fig. 5A and B). These results show that a pair of sgR-
NAs can be used for the deletion of a 3.2 kb segment in one-cell
embryos at high rate, but that the frequency of a 30 kb deletion
falls below 3%. Some founders represent homozygous compound
mutants in the tail and exhibit a coat color phenotype but may
be mosaic mutants in the germline. As observed for the mutant
alleles induced by TALEN, we found that mutant alleles are readily
germline transmitted and that the presence of an ODN bridging the
deletion endpoints could not further support recombination.
3. Discussion
Sequence-speciﬁc nucleases such as TALEN and the CRISPR/Cas
system are increasingly used for editing of single target sites in the
mouse genome for the introduction of small deletions or point
Fig. 4. Deletion of a 3.2 kb Rab38 gene segment in one-cell embryos using Cas9 and two sgRNAs. (A) PCR detection of Rab38D3.2 alleles (primers P-for2 and P-del3) and of
Rab38wt alleles (primers P-for2 and P-rev2, spanning exon 1) with tail DNA from 27 pups derived from embryos microinjected with sgRab38-2, -3 and Cas9 RNAs. Upper gel
image: Eight founders show PCR bands of 326 bp (primers P-forA/P-del3) indicating the presence of Rab38D3.2 alleles; founders #9 and #23 exhibit unexpected, larger PCR
products. Lower gel image: from the founders #6, #8 and #23 the region covering exon 1 of Rab38 could not be ampliﬁed, suggesting that both gene copies were processed by
Cas9. M: size marker, +: positive control, : negative control. (B) Sequence comparison of cloned PCR products derived frommutant founders (see A) with the genomic sgRNA
target regions of Rab38 and the ODND2/3 (sequence insert underlined). The sequencing of 3–5 clones from each founder revealed in six founders the presence of two mutant
alleles. The number of clones classiﬁed as type a or b allele is shown in brackets. The deletion endpoints are either located at the DSB site 3 bp upstream of the sgRNA’s PAM
sequence (red arrows) or show the loss of additional nucleotides, leading to the disruption of the Rab38 reading frame between codon 34 and 37. In the aberrant alleles #9b
and #23b the deleted 3.2 kb region was replaced by sequence inserts of 398 bp (#9b) or 163 bp (#23b) that are derived from the Rab38 gene, located upstream (#9b) or
downstream (#23b) of the sgRab38-3 target sequence. (C) Comparison of the coat color of founder #8 and #23 with an agouti colored littermate control (Rab38WT) and of
dorsal awls showing the reduced pigmentation of hairs in founder #8 (right insert; 40 magniﬁcation).
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tested the possibility of targeting two distant sites in a single step
using two TALEN or sgRNAs for the generation of genomic dele-
tions in the Rab38 gene in one cell embryos. Since a typical dayof embryo microinjection yields 20–30 pups, a deletion frequency
of >3% is required to obtain at least one mutant. We found that a
10 kb deletion could be generated in 6% of pups derived frommicr-
oinjections of two TALEN pairs and that two sgRNAs enabled the
Fig. 5. Germline transmission of Rab38D3.2 alleles. (A) PCR detection of Rab38D3.2 alleles (primers P-for/P-del3) using tail DNA from pups derived frommatings of the indicated
mutant founders with wildtype mice. M: size marker, +: positive control, : negative control. (B) Sequence comparison of PCR products (see A) obtained from the indicated
pups with the parental Rab38D3.2 alleles. The number of deleted basepairs is indicated.
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tion was not obtained among 38 mice.
These deletions reﬂect the spontaneous joining between the
distant ends of two DSBs by NHEJ repair. We reasoned that a
reduced frequency can be expected with increasing DSB distances
and that the junction of such ends may be further promoted by HR
repair and ODNs including homology sequences to the DSB ends.
We found that ODNs did not promote the rejoining of such ends,
indicating that NHEJ but not HR is the predominant DSB repair
mechanism in mammalian cells. Nevertheless, we observed the
deletion of 30 kb or 50 kb in Neuro2A cells. This indicates that lar-
ger deletions can be obtained, but likely occur at a reduced fre-
quency. In a recent study using Mel cells it has been found that
clones with deletions of up to 1 Mb can be readily obtained if the
cells transfected with CRISPR/Cas plasmids are enriched [16]. Inthis study the deletion frequency is inversely related to its size,
predicting 25% efﬁciency for the deletion of 3 kb and 10% efﬁciency
for the deletion of 30 kb. Nevertheless, this relation was delineated
from the top 3% population of transfected cells. Therefore, the
selection of microinjected embryos showing high levels of nuclease
expression may further increase the yield of mutant founders. This
could be achieved in future by the expression of a Cas9-venus
fusion protein, culture of microinjected zygotes to 2-cell embryos
and the selection of embryos showing highest ﬂuorescence for
transfer into foster mothers. Furthermore, it may be possible to
increase the rate of larger deletions. This could be achieved by tar-
geting genomic sites for which long range interactions are known
to occur within topological domains. Thus, the DSB ends can meet
at a higher probability [17]. Alternatively, the joining of distant
DSB ends could be promoted by the selective dimerization of
C. Brandl et al. / FEBS Open Bio 5 (2015) 26–35 33nuclease molecules that are bound to their target sequence. This,
however, will require the development of new technology that
builds on controlled dimerization that depends on conformational
changes that occur upon speciﬁc DNA binding of TALEN or Cas9
[18].
As previously reported for TALEN- and CRISPR/Cas-induced
mutations [19,11], many of our founders harbor two modiﬁed
alleles, together with or without a wildtype Rab38 allele, as identi-
ﬁed by the analysis of tail DNA. Five founders appeared as homo-
zygous compound mutants in the tail tissue and skin
melanocytes leading to a coat color phenotype. Since two of the
three CRISPR/Cas derived homozygous mutants identiﬁed by tail
DNA analysis transmitted a wildtype allele to some of their pups,
individual founders harbor variable patterns of Rab38 alleles in dif-
ferent tissues. Nevertheless, all of the mutant alleles identiﬁed in
the tail were also transmitted to the founders’ progeny, validating
the analysis of tail DNA, in qualitative terms, as predictive of the
founders’ germline. The use of single sgRNAs for DSB induction
can lead to the processing of related off-target sites in the genome
[20–22]. We used target sequences predicted for high speciﬁcity
and analyzed the sequence of three potential off-target sites pre-
dicted for sgRab38-2 and sgRab38-3 using tail DNA of 10 founder
mice. Although we found no evidence for the processing of these
sites in any of these founders, the recognition of other sites can
presently not be excluded.
We showed that both TALEN and sgRNA pairs can be used to
induce genomic deletions in one-cell embryos. Since gene seg-
ments of different lengths were deleted, we could not directly
compare the efﬁciency of both systems. The advantage of CRISPR/
Cas mutagenesis is the simplicity of programming sgRNAs to new
target sequences by cloning of short oligodeoxynucleotides, as
compared to the construction of 1.5 kb coding regions for TALEN
proteins. Nevertheless, TALEN pairs spanning a 30 bp recognition
sequence may be advantageous for excluding off-target effects that
are hard to control for sgRNAs and wildtype Cas9 [20–22]. The use
of shortened sgRNAs [23] and of sgRNA pairs together with a Cas9
nickase mutant [24] have been described as strategies for increas-
ing the speciﬁcity of DSB induction by CRISPR/Cas. Since the nick-
ase approach has been recently validated for the targeting of single
sites in one-cell mouse embryos [25], the use of such sgRNA pairs
should be explored for the future generation of targeted deletions
by CRISPR/Cas. Our results show that each of these nuclease sys-
tems can be used to create genomic deletions. Therefore, the choice
of TALEN or CRISPR/Cas may depend on the speciﬁcs of individual
experiments.
Using TALEN or CRISPR/Cas in one cell embryos enables the
identiﬁcation of mutant founders, just 7 weeks after microinjection
[26,27]. It is therefore considerably faster in comparison to ES cell
technology. Moreover, creating large deletions in ES cells requires
the construction of gene targeting vectors and the manipulation
of two distant genomic sites by sequential gene targeting steps
[28]. These constrains are released by the application of nuclease
technology, enabling the expedite generation of deletions in the
mouse germline. Targeted deletions are of use to study structural
genome variation that occurs between individuals of the same spe-
cies or between related species. In mice targeted deletions could be
applied for modeling of human disease associated genomic dele-
tions [13] or to explore the consequences of deletions found specif-
ically in the human genome [29]. Furthermore, it will be possible
to derive new, improved inbred mouse strains, e.g. by the removal
of deleterious retroviral insertions [30–32]. Besides the straightfor-
ward deletion of genomic sequences it will be interesting to
explore in future whether genomic deletions can be combined with
the insertion of new genes or gene segments to achieve single step
gene replacements.4. Materials and methods
4.1. TALEN construction and expression
TALEN target sites were selected using the ‘‘TALENdesigner’’
(www.talen-design.de) as described [26]. Selected target sites
cover two recognition sequences of 15 bp, preceded by a T and sep-
arated by a spacer of 15 bp. TALEN construction and expression
was carried out as described using the expression vectors pCAG-
TALEN-pA [11] and pT7-95A [33]. For sequence recognition of the
TAL RVDs see Table 1. The targeting oligodeoxynucleotide ODN (A/
B) was synthesized and HPLC puriﬁed by Metabion (Martinsried,
Germany). ODN (A/B) sequence (BamHI site underlined): tggtgatcg
gcgacctgggtgtgggcaagaccagcattatcaagcgctatgtgcaccaaaaactggatcc
actattgcttttcattggatatattgagctaattatctag tgaacctattttaggatg ttaatt.4.2. CRISPR/Cas target sites and vector construction
CRISPR target sites were identiﬁed using http://crispr.mit.edu/
as described [34]. In order to create differently sized genomic dele-
tions in Neuro2A cells, four different sgRNAs target sequences of
20 bp located upstream of a NGG PAM-sequence were selected.
Selected target sequences (underlined) were cloned as comple-
mentary oligonucleotides in between two BbsI sites of a Bluescript
plasmid containing a U6 promoter (pBS-U6) and the sgRNA back-
bone [34] for the production of RNA from the template sequence
of sgRab38-2 cloned into pBS-U6-sgRab38-2: AAAACTTCTCCTCGC
ACTACGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGT
TATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT, of sgRab38-
3 cloned into pBS-U6-sgRab38-3:
GGCCCTCTCATCAAGAGCGACGTTTTAGAGCTAGAAATAGCAAGTT
AAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGG
TGCTTTTTTT, of sgRab38-10 cloned into pBS-U6-sgRab38-10:
GTTTGTAAATATCCGCATATTGTTTTAGAGCTAGAAATAGCAAGTTA
AAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGT
GCTTTTTTT, of sgRab38-32 cloned into pBS-U6-sgRab38-32:
CTTGTGTAGCCGCACCCATGGTTTTAGAGCTAGAAATAGCAAGTTA
AAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGT
GCTTTTTTT, and of sgRab38-52 cloned into pBS-U6-sgRab38-52:
TGCTTTTCCCAATAATCGTTGTTTTAGAGCTAGAAATAGCAAGTTAA
AATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTG
CTTTTTTT.
For the production of sgRNAs by in vitro transcription a T7 pro-
moter sequence (TAATAATACGACTCACTATAG) was added
upstream of the target sequence. To assess potential CRISPR off-
target activity, three high-scored off-target sites (see Supplemen-
tary Fig. 2) were ampliﬁed by the locus-speciﬁc primer pairs
shown in Table 2. For analysis the PCR products were puriﬁed,
sequenced (GATC Biotech, Konstanz, Germany) and compared to
wild type using the Vector NTI Advance 11.5 (Life Technologies)
and Chromas (Technelysium) software. For the expression of
Cas9 we replaced the TAL sequences of our pTALEN-pA plasmid
with a T7 promoter and a codon optimized Cas9 coding region
[35] purchased from Genscript (Piscataway, USA) to derive the
pCAG-Cas9-pA expression vector. For the production of Cas9 mRNA
we inserted the Cas9 coding region into our pT7-95A plasmid that
was further modiﬁed by the addition of 67 A residues to derive the
plasmid pCAG-Cas9-162A.
The targeting oligodeoxynucleotide ODND2/3 was synthesized
and HPLC puriﬁed by Metabion (Martinsried, Germany). ODND2/
3 sequence (BamHI site underlined): ACCTGGGTGTGGGCAAGACC
AGCATTATCAAGCGCTATGTGCACCAAAACTTCTCCTCGCACTACACT
GGATCCACTGTCGCTCTTGATGAGAGGGCAGGGATTTCCCCTGACTCT
ATAGGATATTAGCCTACTGCAA.
Table 2
Primer pairs used for the ampliﬁcation of high-scored off-target sites.
Off target name Forward primer (50–30) Reverse primer (50–30)
sgRab38-2: OT2-1 TTGAGGAGGATTTCTGTATGTGTGTGTTG CTAGAACATTAACCATGCAAGTTCTTATTGAC
sgRab38-2: OT2-2 TGGGTGAGAGACAGGGACCCTCATG GCCTTACCCTGGATCTTGGCAGCAG
sgRab38-2: OT2-3 CCTGGGACAAGGAGGAGGAGGAAGAG CATTCGCGTCCTCTAACGCAAATGAC
sgRab38-3: OT3-1 CATGAGTGACCTAAGATACCCAGCACCTG GCACCACATGAAAGCTGGTGCTCAAG
sgRab38-3 OT3-2 AATCAAAATCATCTGCCTCCAAATGCTC GATGTTCTGTCCACAGGGATGTCTGTG
sgRab38-3: OT3-3 AGCTCGGGACTTCAGTTCAAGTCACTTG TGACCAGCAGAAGCACCATCACCAC
Table 1
TAL RVDs used for DNA sequence recognition.
Rab38 TAL-A1
TALEN RVD sequence NI NG HD NI NI NN HD NN HD NG NI NG NN NG
Target sequence (50–30) A T C A A G C G C T A T G T
Rab38 TAL-A2
TALEN RVD sequence NN NN HD HD HD NN NN NG NI NN NG NN HD NN
Target sequence (50–30) G G C C C G G T A G T G C G
Rab38 TAL-B1
TALEN RVD sequence NG NG HD NI NI NI NG NN HD NG NI NI NG NI
Target sequence (50–30) T T C A A A T G C T A A T A
Rab38 TAL-B1
TALEN RVD sequence HD NI NI NG NI NG NI NG HD HD NI NI NG NN
Target sequence (50–30) C A A T A T A T C C A A T G
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Nuclease reporter plasmids were generated by the insertion of
annealed sense and anti-sense oligonucleotides (Metabion, Mar-
tinsried, Germany), harboring TALEN and sgRNA target sequences,
into the generic reporter plasmid pTAL-Rep, as described [11]. The
integrity of all reporter plasmids was conﬁrmed by DNA sequenc-
ing. For the assessment of nuclease activities, expression vectors
were cotransfected with the corresponding reporter plasmid into
Neuro2A cells (No. ACC 148, DSMZ, Braunschweig, Germany).
Two days after transfection the cells were lysed and b-galactosi-
dase was determined by chemiluminescence, as described [11].
4.4. Deletions in Neuro2A cells
To create deletions in Neuro2A cells, pairs of sgRNA vectors and
pCAG-Cas9-pA plasmid DNA were cotransfected using the X-trem-
GENE reagent (Roche). Two days later genomic DNA was isolated
using the Wizard Genomic DNA Puriﬁcation Kit and used for the
detection of deleted alleles as described below.
4.5. Microinjection of one-cell embryos
The injection of TALEN mRNA and targeting molecules (ODNs)
was performed as described [33], except that injections were done
only into pronuclei. Brieﬂy, capped TALENmRNAwas prepared in a
single step by in vitro transcription from pT7-TALEN-95A plasmids
(linearized with XbaI and AleI) or from pCAG-Cas9-162A (linear-
ized with AsiSi and XbaI) using the mMessage mMachine T7 Ultra
kit (Ambion, AM1345, Life Technologies, Carlsbad, USA) (omitting
the polyadenylation step) and the MEGAclear kit (Ambion,
#1908). sgRNAs were prepared using templates ampliﬁed by PCR
from pBS-U6-sgRNA plasmids (primer T7-tracr1: GTACAAAA
TACGTGACGTAGAAAG; T7-tracr2: AAAAAAAGCACCGACTCGGTG)
for in vitro transcription using the Megashortscript kit (Ambion,
#AM1354) and puriﬁcation with the MEGAclear kit. The quality
of mRNAs (TALEN, Cas9) was controlled by agarose gel electropho-
resis under denaturing conditions using the NorthernMax-Gly sys-
tem and the RNA Millennium size marker (Life Technologies) or forsgRNAs using a Bioanalyzer and the RNA 6000 Nano chip (Agilent,
Santa Clara, CA, USA). TALEN mRNAs were diluted in microinjec-
tion buffer (10 mM Tris, 0.1 mM EDTA, pH 7.2) to a working con-
centration each of 45 ng/lL; Cas9 mRNA and sgRNAs were used
at concentrations of 67 ng/lL or 30 ng/lL, respectively. The target-
ing oligodeoxynucleotides were dissolved in water and diluted
with injection buffer to a working concentration of 30 ng/lL. For
microinjections, one-cell embryos were obtained by mating of
(DBA/2  C57BL/6) F1 males with superovulated FVB/N females
(Charles River, Sulzbach, Germany). One-cell embryos were
injected into the larger pronucleus, but not into the cytoplasm.
Injected zygotes were transferred into pseudopregnant CD1 female
mice to obtain live pups. All mice showed normal development and
appeared healthy. Mice were handled according to institutional
guidelines approved by the animal welfare and used committee
of the government of upper Bavaria and housed in standard cages
in a speciﬁc pathogen-free facility on a 12 h light/dark cycle with
ad libitum access to food and water.
4.6. DNA isolation and genotyping of mutant founders and their
offspring
Genomic DNA was isolated from tail tips of founder mice and
biopsies of their progeny, using the Wizard Genomic DNA Puriﬁca-
tion Kit (Promega, Mannheim, Germany), following the manufac-
turer’s instructions. For the genotyping of founder mice and their
progeny, PCR reactions using 1 lL genomic DNA (100 ng) and
1 lL of each appropriate primer (10 lM) was carried out in a total
volume of 25 lL using the 5 PRIME Mastermix (5 PRIME GmbH,
Hilden, Germany) and PCR steps of: 94 C – 5 min; {94 C – 40 s;
60 C – 40 s; 72 C – 60 s} for 30 cycles; 72 C – 10 min. For the
detection of TALEN induced deletions we used the primer pair
P-forA (AAGCTCCAGGCTCCGCAAGAC) and P-revA (CCGAACTCCTC
ACTGGCTCAC) to amplify the TALEN-A1/2 region, the primer pair
P-forB (AATGCTACTGTGTTTGCCTTGG) and P-del (CATCTCAAATGTT
GGGATCACAAG) to amplify the TALEN-B1/2 region and the primers
P-forA and P-del to detect Rab38D9.3 alleles. For the detection of
CRISPR/Cas induced deletions we used the primer pairs P-for2
(CACATAGAGCTCCGGTCTCC) and P-rev2 (CGAACTCCTCACTGGCT
C. Brandl et al. / FEBS Open Bio 5 (2015) 26–35 35CAC) to amplify the sgRab38-2 region, the primer pair P-for3
(AACTTCTGTTCTTCTTTCCTGTGC) and P-del3 (TACGAATCAGACC
TTACATCAGTG) to amplify the sgRab38-3 region, and the primer
pairs P-for2 and P-del3, or P-del10 (GTACCTAGAGCCTCGAGCTG),
P-del32 (CGCTAGGAAATCTGGTTAGTG), or P-del52 (GGTCCATATT
TACAGTCACACCT) for the detection of large deletions. For the anal-
ysis of gene editing PCR products were sequenced and analyzed
using the TIDE tool [36]. For the subcloning of mutant alleles,
PCR reactions were carried out using Herculase II Fusion polymer-
ase (Agilent, Waldbronn, Germany) in a total volume of 50 lL with
30 cycles of {98 C, 20 s; 60 C, 20 s; 72 C, 20 s}. PCR products were
puriﬁed using the Qiaquick PCR puriﬁcation kit (QIAGEN, Hilden,
Germany), subcloned using the StrataClone Blunt PCR Cloning Kit
(Agilent) and sequenced (GATC Biotech, Konstanz, Germany).
Sequences were compared to wild type, using the Vector NTI
Advance 11.5 software suite (Life Technologies).
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